SEC Comment Letter 0000000000-23-001896 to CytoMed Therapeutics Ltd (GDTC)
CytoMed Therapeutics Ltd
Date: Feb. 24, 2023 · CIK: 0001873093 · Accession: 0000000000-23-001896
AI Filing Summary & Sentiment
File numbers found in text: 333-268456
Letter
United States securities and exchange commission logo February 24, 2023 Chee Kong Choo Director and Chairman CytoMed Therapeutics Pte. Ltd. 21 Bukit Batok Crescent #17-80 WCEGA Tower Singapore 658065 Re:CytoMed Therapeutics Pte. Ltd. Amendment No. 2 to Registration Statement on Form F-1 Filed February 1, 2023 File No. 333-268456 Dear Chee Kong Choo: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Amendment No. 2 to Registration Statement on Form F-1 Business Overview, page 89 1.We note the revisions to the pipeline on page 90, so that there are now four columns prior to Phase 1: discovery, process development, preclinical studies, and trial application. Revise the pipeline table to combine these four columns into no more than two columns, each no wider or more prominent than each of the phases of clinical development. Also revise the table so that each row has one arrow that begins on the left and progresses to the point of current development, rather than multiple arrows within each column.
FirstName LastNameChee Kong Choo Comapany NameCytoMed Therapeutics Pte. Ltd. February 24, 2023 Page 2 FirstName LastName Chee Kong Choo CytoMed Therapeutics Pte. Ltd. February 24, 2023 Page 2 You may contact Tracie Mariner at (202) 551-3744 or Daniel Gordon at (202) 551- 3486 if you have questions regarding the financial statements and related matters. Please contact Abby Adams at (202) 551-6902 or Celeste Murphy at (202) 551-3257 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard I. Anslow, Esq.
Show Raw Text
United States securities and exchange commission logo
February 24, 2023
Chee Kong Choo
Director and Chairman
CytoMed Therapeutics Pte. Ltd.
21 Bukit Batok Crescent
#17-80 WCEGA Tower
Singapore 658065
Re:CytoMed Therapeutics Pte. Ltd.
Amendment No. 2 to Registration Statement on Form F-1
Filed February 1, 2023
File No. 333-268456
Dear Chee Kong Choo:
We have reviewed your amended registration statement and have the following
comment. Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.
Amendment No. 2 to Registration Statement on Form F-1
Business
Overview, page 89
1.We note the revisions to the pipeline on page 90, so that there are now four columns prior
to Phase 1: discovery, process development, preclinical studies, and trial application.
Revise the pipeline table to combine these four columns into no more than two columns,
each no wider or more prominent than each of the phases of clinical development. Also
revise the table so that each row has one arrow that begins on the left and progresses to the
point of current development, rather than multiple arrows within each column.
FirstName LastNameChee Kong Choo
Comapany NameCytoMed Therapeutics Pte. Ltd.
February 24, 2023 Page 2
FirstName LastName
Chee Kong Choo
CytoMed Therapeutics Pte. Ltd.
February 24, 2023
Page 2
You may contact Tracie Mariner at (202) 551-3744 or Daniel Gordon at (202) 551-
3486 if you have questions regarding the financial statements and related matters. Please contact
Abby Adams at (202) 551-6902 or Celeste Murphy at (202) 551-3257 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Richard I. Anslow, Esq.